PMID- 30293914
OWN - NLM
STAT- MEDLINE
DCOM- 20191118
LR  - 20211204
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 42
IP  - 3
DP  - 2019 Mar
TI  - Elimination of hepatitis C virus infection from a hemodialysis unit and impact of 
      treatment on the control of anemia.
PG  - 164-170
LID - S0210-5705(18)30252-8 [pii]
LID - 10.1016/j.gastrohep.2018.07.015 [doi]
AB  - INTRODUCTION: In the interferon era, the treatment of hepatitis C virus (HCV) 
      infection in patients on haemodialysis (HD) was limited due to the significant 
      number of treatment-related adverse events (AEs). Direct-acting antivirals (DAAs) 
      have demonstrated their efficacy and safety in the treatment of HCV in patients 
      with advanced chronic kidney disease on haemodialysis. The objective of the study 
      was to evaluate the success in eliminating HCV infection from our dialysis unit 
      using DAAs, and to assess the impact of HCV elimination on clinical and 
      analytical outcomes. PATIENTS AND METHODS: This is a prospective, interventional, 
      single-center study at Hospital Clinic de Barcelona. All HCV-RNA positive 
      patients who received antiviral therapy with DAAs within a 3-year period 
      (2014-2017) were analyzed (n=20). Data on virologic response, adverse events, and 
      biochemical and hematological parameters during and after DAA therapy were 
      analyzed. RESULTS: All patients achieved sustained virologic response (SVR) and 
      only 40% of patients presented with mild AEs. None of the patients presented with 
      HCV reinfection after a 1-year follow-up period, and thus HCV was eliminated from 
      our HD unit. SVR was associated with a significant increase in hemoglobin and 
      hematocrit, and a tendency toward the need for lower doses of iron 
      supplementation with no changes in darbepoetin dose. CONCLUSION: HCV infection 
      can be safely eliminated from HD units with the use of DAAs, preventing new 
      infections in patients and healthcare staff. In the short term, the achievement 
      of SVR is associated with an improvement in the control of anemia.
CI  - Copyright (c) 2018 Elsevier Espana, S.L.U. All rights reserved.
FAU - Maduell, Francesc
AU  - Maduell F
AD  - Department of Nephrology, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Belmar, Lara
AU  - Belmar L
AD  - Department of Nephrology, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Ugalde, Jesica
AU  - Ugalde J
AD  - Department of Nephrology, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Laguno, Montserrat
AU  - Laguno M
AD  - HIV/AIDS Unit, Infectious Disease Service, Hospital Clinic, University of 
      Barcelona, Barcelona, Spain.
FAU - Martinez-Rebollar, Maria
AU  - Martinez-Rebollar M
AD  - HIV/AIDS Unit, Infectious Disease Service, Hospital Clinic, University of 
      Barcelona, Barcelona, Spain.
FAU - Ojeda, Raquel
AU  - Ojeda R
AD  - Department of Nephrology, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Arias, Marta
AU  - Arias M
AD  - Department of Nephrology, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Rodas, Lida
AU  - Rodas L
AD  - Department of Nephrology, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Rossi, Florencia
AU  - Rossi F
AD  - Department of Nephrology, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Llovet, Laura-Patricia
AU  - Llovet LP
AD  - Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, University of 
      Barcelona, Barcelona, Spain.
FAU - Gonzalez, Leonardo Nicolas
AU  - Gonzalez LN
AD  - Department of Nephrology, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Mallolas, Josep
AU  - Mallolas J
AD  - HIV/AIDS Unit, Infectious Disease Service, Hospital Clinic, University of 
      Barcelona, Barcelona, Spain.
FAU - Londono, Maria-Carlota
AU  - Londono MC
AD  - Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, University of 
      Barcelona, Barcelona, Spain. Electronic address: mlondono@clinic.cat.
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Observational Study
DEP - 20181004
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Anilides)
RN  - 0 (Antiviral Agents)
RN  - 0 (Carbamates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Hematinics)
RN  - 0 (Lactams, Macrocyclic)
RN  - 0 (Macrocyclic Compounds)
RN  - 0 (Sulfonamides)
RN  - 15UQ94PT4P (Darbepoetin alfa)
RN  - 2302768XJ8 (ombitasvir)
RN  - 56HH86ZVCT (Uracil)
RN  - 9034-51-9 (Hemoglobin A)
RN  - 9DLQ4CIU6V (Proline)
RN  - CKR7XL41N4 (2-Naphthylamine)
RN  - DE54EQW8T1 (dasabuvir)
RN  - HG18B9YRS7 (Valine)
RN  - O3J8G9O825 (Ritonavir)
RN  - OU2YM37K86 (paritaprevir)
SB  - IM
MH  - 2-Naphthylamine
MH  - Anemia/*drug therapy/etiology
MH  - Anilides
MH  - Antiviral Agents/*therapeutic use
MH  - Carbamates
MH  - Cyclopropanes
MH  - Darbepoetin alfa/administration & dosage
MH  - Female
MH  - Hematinics/administration & dosage
MH  - Hematocrit
MH  - Hemoglobin A
MH  - Hepatitis C/*drug therapy
MH  - Humans
MH  - Lactams, Macrocyclic
MH  - Macrocyclic Compounds/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Proline/analogs & derivatives
MH  - Prospective Studies
MH  - *Renal Dialysis
MH  - Renal Insufficiency, Chronic/complications/*therapy
MH  - Ritonavir/therapeutic use
MH  - Sulfonamides/therapeutic use
MH  - *Sustained Virologic Response
MH  - Uracil/analogs & derivatives/therapeutic use
MH  - Valine
OTO - NOTNLM
OT  - Eliminacion
OT  - Elimination
OT  - Hemodialysis
OT  - Hemodialisis
OT  - Hepatitis C virus
OT  - Respuesta viral sostenida
OT  - Sustained virologic response
OT  - Virus de la hepatitis C
EDAT- 2018/10/09 06:00
MHDA- 2019/11/19 06:00
CRDT- 2018/10/09 06:00
PHST- 2018/06/07 00:00 [received]
PHST- 2018/07/23 00:00 [revised]
PHST- 2018/07/29 00:00 [accepted]
PHST- 2018/10/09 06:00 [pubmed]
PHST- 2019/11/19 06:00 [medline]
PHST- 2018/10/09 06:00 [entrez]
AID - S0210-5705(18)30252-8 [pii]
AID - 10.1016/j.gastrohep.2018.07.015 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2019 Mar;42(3):164-170. doi: 
      10.1016/j.gastrohep.2018.07.015. Epub 2018 Oct 4.